A Multicenter, Randomized, Double-blind, Placebo-controlled Dose-finding Phase 2 Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia
Latest Information Update: 17 Jan 2022
At a glance
- Drugs YH 12852 (Primary)
- Indications Dyspepsia
- Focus Therapeutic Use
- Sponsors Yuhan
- 26 Dec 2021 Status changed from suspended to discontinued.
- 06 Sep 2018 Planned End Date changed from 1 Jan 2017 to 1 Jan 2020.
- 06 Sep 2018 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2020.